UPL is currently trading at Rs. 675.50, up by 1.10 points or 0.16% from its previous closing of Rs. 674.40 on the BSE.
The scrip opened at Rs. 678.20 and has touched a high and low of Rs. 687.95 and Rs. 668.05 respectively. So far 329261 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 687.95 on 11-May-2021 and a 52 week low of Rs. 336.55 on 20-May-2020.
Last one week high and low of the scrip stood at Rs. 687.95 and Rs. 619.00 respectively. The current market cap of the company is Rs. 52042.03 crore.
The promoters holding in the company stood at 27.96%, while Institutions and Non-Institutions held 53.76% and 10.12% respectively.
UPL’s subsidiary has entered into a license agreement with Japanese company, Meiji Seika Pharma for exclusive access to Flupyrimin for rice in Southeast Asia. Under the license agreement, UPL will obtain exclusive rights to develop, register and commercialize formulations of Flupyrimin for foliar applications in rice in Southeast Asia, expanding the on-going collaboration between the two companies with this compound. Together, both companies will continue their contributions to the development of differentiated solutions based on Flupyrimin to address farmer pain points and improve their livelihoods.
UPL is global player of crop protection products has customer base in 123 countries. It has subsidiary offices in Argentina, Australia, Bangladesh, Brazil, China, Canada, Denmark, Indonesia, France, Hong Kong, Japan, Korea, Mauritius, Mexico, New Zealand, Russia, Spain, Taiwan, South Africa, USA, UK, Vietnam and Zambia.